This paper is a concise, outlined-based summary of a virtual roundtable meeting conducted on March 26, 2020. The roundtable was organized by Blue Matter and included a panel of biopharma executives and other experts that have proven track records of success in Europe.
In this first, virtual roundtable event, the group was asked to consider a biopharma company’s journey to Europe in three stages:
- Evaluating European Market Entry
- Deciding to Enter the European Market
- Entering Europe
Within each stage, the group was asked to share three things from their
- Critical Questions – What are the most important questions by stage?
- Best Practices – What did success look like and what would you
consider best practice?
- Pain Points – What special challenges did you face, or what would
you do differently if given the chance?
This summary document captures the group’s collective input.